
Eli Lilly and Company has bought a new diagnostic technology which may help point to a different way of treating …

Eli Lilly and Co’s new type II diabetes candidate dulaglutide – which it intends to file this year – has …

The FDA has issued guidance to help companies developing new treatments for patients with early-stage Alzheimer’s disease. The US regulator’s …
A round-up of pharma manufacturing news, including facility updates from MeadWestvaco, Rexam, Almac, UPS and Kemwell Biopharma. MeadWestvaco has said …

Lilly is abandoning its late-stage trial into investigational rheumatoid arthritis (RA) drug tabalumab but insists the move has nothing to …

A survey released to tie in with today’s World Cancer Day finds that most people feel pharma companies see cancers …
The loss of exclusivity on Eli Lilly’s blockbuster antipsychotic Zyprexa hit the company hard in 2012, with the firm’s overall …

Eli Lilly’s diagnostic radiopharmaceutical Amyvid has been approved in Europe to assess whether patients have Alzheimer’s disease. Amyvid (Florbetapir F …

Patient groups have welcomed NICE’s new draft guideline recommending the use of preventive treatments in women who have a family …
Boehringer Ingelheim has handed back one of Eli Lilly’s investigational diabetes drugs as a result of ‘independent strategic portfolio considerations’. …

Fine chemicals company Evonik Degussa has announced job cuts as part of an efficiency drive at a US plant making …

AstraZeneca and Eli Lilly have both suffered setbacks in their attempts to push their respective investigational rheumatoid arthritis (RA) treatments …

Lilly UK has appointed Dr Jean-Michel Cosséry as the new managing director and VP of the UK Affiliate and the …

A study of Janssen Pharmaceuticals’ Razadyne suggests that the Alzheimer’s drug helped patients stay alive longer and slowed their cognitive …

Eli Lilly has unveiled plans for a $140 million expansion of its insulin plant in Indianapolis as it starts to …